Introduction to diabetes

In this section, you can learn about the epidemiology of type 2 diabetes and its links to obesity as well as watch physician and patient thoughts on the future of diabetes. You can also view a presentation by Dr Edwin B Villhauer who led the team that discovered the first DPP-4 inhibitor, vildagliptin, get a concise view of the ESC guidelines on renin-angiotensin system (RAS) blockers as well as read four recent publications that marked the recent 10th anniversary of the vildagliptin.

Epidemiology

Epidemiology<br></br>

The statistics are truly worrying, but trials are now showing ways we can look to improve long-term outcomes. Find out more what could be done to overcome this growing problem.

The benefits of RAS blockers

The benefits of RAS blockers

Watch the video to find out more about DDP-4 inhibitors. Find out how RAS blockers can reduce risk of microalbuminuria and what the ESC guidelines recommend.

Ten Years of Vildagliptin

Ten Years of Vildagliptin

A comprehensive resource offering summaries and links to publications for key clinical data on vildagliptin.

The Future of Diabetes

The Future of Diabetes<br><br/>

What are the opportunities and challenges? View a presentation of expert physicians debate this question